Novel inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR)

1-脱氧-D-木酮糖-5-磷酸还原异构酶 (DXR) 的新型抑制剂

基本信息

  • 批准号:
    8092590
  • 负责人:
  • 金额:
    $ 19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-18 至 2012-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall objectives of this proposal are to use a combination of traditional medicinal chemistry and computational, structure based drug design to develop novel small molecule inhibitors of 1-deoxy-D-xylulose-5- phosphate reductoisomerase (DXR) and test their in vitro biological activities on pathogenic bacteria and parasites. Isoprene biosynthesis is essential to all organisms. Humans use the mevalonate pathway to produce isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), two common precursors for all isoprenoid biosynthesis; however, in most pathogenic bacteria, such as P. aeruginosa and M. tuberculosis, as well as apicomplexan parasites, such as P. falciparum and T. gondii, the non-mevalonate pathway is used to make IPP and DMAPP. Since humans lack all the 7 enzymes in the non-mevalonate pathway, it has become an attractive target for anti-infective drug discovery. Fosmidomycin has been found to be the only potent inhibitor of this pathway, blocking DXR, the 2nd enzyme, and has antibacterial activity against many Gram- negative bacteria and antimalarial activity in recent clinical trials. However, Gram-positive bacteria (e.g., M. tuberculosis) and some Gram-negative bacteria as well as certain pathogenic parasites (e.g., T. gondii) are resistant to fosmidomycin. In addition, it has a poor pharmacokinetic profile with a half-life in plasma of 0.5-1.5 h. Given the current devastating situation facing quickly rising drug resistance as well as shortage of new anti- infective drugs, there is a pressing need to find new weaponry for infectious diseases. The first Specific Aim is to use a combination of medicinal chemistry and computational, structure based drug design to develop novel inhibitors of DXR. Based on rational, structure based design, we have found novel, drug-like lead inhibitors with Kis as low as 310 nM against a recombinant E. coli DXR enzyme. Our docking studies showed that they could bind to DXR in different modes from that of fosmidomycin. These drug-like compounds should have great potential for further development. We propose 1) to use medicinal chemistry to make several series of compound libraries based on the scaffolds of the lead inhibitors, in order to find compounds with improved activity; 2) to carry out QSAR studies of these compounds; 3) to obtain x-ray crystal structures of DXR in complex with our novel inhibitors; and 4) to use the results from the computational and crystallographic studies to guide our further drug design and synthesis. The second Specific Aim is to test in vitro biological activity of our inhibitors on a broad range of bacteria and apicomplexan parasites as well as their recombinant DXR enzymes. Finally, we will also test the cytotoxicity of our potent DXR inhibitors on human cell lines to evaluate their potential toxicity. PUBLIC HEALTH RELEVANCE: The research proposed is designed to lead to new potential therapeutics to treat drug-resistant infectious diseases. We will focus on the discovery and development of novel compounds that block essential biological targets that are exclusively found in bacteria and malaria parasites.
描述(由申请人提供):本提案的总体目标是使用传统药物化学和基于计算结构的药物设计的组合来开发1-脱氧-D-木酮糖-5-磷酸还原异构酶(DXR)的新型小分子抑制剂,并测试其对病原菌和寄生虫的体外生物活性。异戊二烯的生物合成对所有生物体都是必不可少的。人类使用甲羟戊酸途径产生异戊烯基二磷酸(IPP)和二甲基烯丙基二磷酸(DMAPP),这是所有类异戊二烯生物合成的两种常见前体;结核病,以及顶复门寄生虫,如恶性疟原虫和T.在弓形虫中,非甲羟戊酸途径用于制备IPP和DMAPP。由于人类缺乏非甲羟戊酸途径中的所有7种酶,因此它已成为抗感染药物发现的有吸引力的靶点。已发现磷咪霉素是该途径的唯一有效抑制剂,阻断第二种酶DXR,并且在最近的临床试验中具有针对许多革兰氏阴性细菌的抗菌活性和抗疟疾活性。然而,革兰氏阳性细菌(例如,M.结核)和一些革兰氏阴性细菌以及某些致病性寄生虫(例如,T.弓形虫)对磷霉素具有抗性。此外,其药代动力学特征较差,血浆半衰期为0.5-1.5 h。鉴于目前面临迅速上升的耐药性以及新的抗感染药物短缺的破坏性局势,迫切需要找到新的传染病武器。第一个具体目标是使用药物化学和基于计算结构的药物设计的组合来开发新型DXR抑制剂。基于合理的、基于结构的设计,我们发现了新的、药物样的先导抑制剂,其对重组大肠杆菌的Ki低至310 nM。coliDXR酶。我们的对接研究表明,他们可以结合DXR在不同的模式,从磷霉素。这些类药物化合物应该具有进一步开发的巨大潜力。我们建议:1)利用药物化学的方法,以先导化合物为骨架构建多个系列的化合物库,寻找活性更高的化合物; 2)对这些化合物进行QSAR研究; 3)获得DXR与我们的新型抑制剂复合物的X-射线晶体结构; 4)利用计算和晶体学研究的结果指导我们进一步的药物设计和合成。第二个具体目标是测试我们的抑制剂对广泛的细菌和顶复门寄生虫及其重组DXR酶的体外生物活性。最后,我们还将测试我们的强效DXR抑制剂对人类细胞系的细胞毒性,以评估其潜在毒性。 公共卫生相关性:拟议的研究旨在开发新的潜在疗法来治疗耐药性传染病。我们将专注于发现和开发新型化合物,这些化合物可以阻断细菌和疟疾寄生虫中特有的重要生物靶标。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Antimalarial and Structural Studies of Pyridine-containing Inhibitors of 1-Deoxyxylulose-5-phosphate Reductoisomerase.
  • DOI:
    10.1021/ml300419r
  • 发表时间:
    2013-02-14
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Xue, Jian;Diao, Jiasheng;Cai, Guobin;Deng, Lisheng;Zheng, Baisong;Yao, Yuan;Song, Yongcheng
  • 通讯作者:
    Song, Yongcheng
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yongcheng Song其他文献

Yongcheng Song的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yongcheng Song', 18)}}的其他基金

Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia
针对小儿白血病致癌融合 MLL 的新型小分子探针
  • 批准号:
    10340987
  • 财政年份:
    2021
  • 资助金额:
    $ 19万
  • 项目类别:
Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia
针对小儿白血病致癌融合 MLL 的新型小分子探针
  • 批准号:
    10539338
  • 财政年份:
    2021
  • 资助金额:
    $ 19万
  • 项目类别:
Novel small-molecule inhibitors of SARS-CoV-2 protease
新型 SARS-CoV-2 蛋白酶小分子抑制剂
  • 批准号:
    10200270
  • 财政年份:
    2020
  • 资助金额:
    $ 19万
  • 项目类别:
Chemical Probes Targeting Gliomas with IDH Mutation
针对 IDH 突变神经胶质瘤的化学探针
  • 批准号:
    8732716
  • 财政年份:
    2012
  • 资助金额:
    $ 19万
  • 项目类别:
Chemical Probes Targeting Gliomas with IDH Mutation
针对 IDH 突变神经胶质瘤的化学探针
  • 批准号:
    8925163
  • 财政年份:
    2012
  • 资助金额:
    $ 19万
  • 项目类别:
Chemical Probes Targeting Gliomas with IDH Mutation
针对 IDH 突变神经胶质瘤的化学探针
  • 批准号:
    8551785
  • 财政年份:
    2012
  • 资助金额:
    $ 19万
  • 项目类别:
Chemical Probes Targeting Gliomas with IDH Mutation
针对 IDH 突变神经胶质瘤的化学探针
  • 批准号:
    9136239
  • 财政年份:
    2012
  • 资助金额:
    $ 19万
  • 项目类别:
Chemical Probes Targeting Gliomas with IDH Mutation
针对 IDH 突变神经胶质瘤的化学探针
  • 批准号:
    8418824
  • 财政年份:
    2012
  • 资助金额:
    $ 19万
  • 项目类别:
Novel Metallo-beta-lactamase Inhibitors
新型金属-β-内酰胺酶抑制剂
  • 批准号:
    8075426
  • 财政年份:
    2010
  • 资助金额:
    $ 19万
  • 项目类别:
Novel inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR)
1-脱氧-D-木酮糖-5-磷酸还原异构酶 (DXR) 的新型抑制剂
  • 批准号:
    7989076
  • 财政年份:
    2010
  • 资助金额:
    $ 19万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 19万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 19万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 19万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 19万
  • 项目类别:
    Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 19万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 19万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
  • 批准号:
    23KK0126
  • 财政年份:
    2023
  • 资助金额:
    $ 19万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 19万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 19万
  • 项目类别:
    Training Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了